evolocumab
Sign in to saveAlso known as AMG-145
Evolocumab, sold under the brand name Repatha, is a monoclonal antibody that is an immunotherapy medication for the treatment of hyperlipidemia.
Key facts
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- PCSK9
- Drug.pronounce
- e-voe-LOK-ue-mab
- Drug.tradename
- Repatha
- Drug.DailyMedID
- Evolocumab
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- Subcutaneous
- Drug.ATC_prefix
- C10
- Drug.ATC_suffix
- AX13
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.legal_status
- Rx-only
- Drug.CAS_number
- 1256937-27-5
- Drug.ChemSpiderID
- none
via Wikipedia infobox
Research
1,492 papers- Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.The New England journal of medicine · 2026
- Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.Circulation · 2022
- Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor.Clinical pharmacokinetics · 2018
- Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction.JACC. Cardiovascular imaging · 2022
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.JAMA · 2016
via PubMed
~6 min read
Encyclopedic overview
6 sectionsContents
- Mechanism
- Adverse effects
- History
- Society and culture
- Economics
- References
Evolocumab, sold under the brand name Repatha, is a monoclonal antibody that is an immunotherapy medication for the treatment of hyperlipidemia.
Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation; its inhibition thereby enhances the liver's ability to remove LDL-C, often colloquially referred to as "bad" cholesterol, from the blood.
Excerpted from Wikipedia’s “evolocumab” article, available under the CC BY-SA 4.0 licence.